Articles tagged with Antivirals
A laboratory study by Vanderbilt University Medical Center researchers detected COVID-19 virus developing resistance to remdesivir through mutations in the polymerase enzyme. The study highlights the importance of monitoring for resistance and developing combination therapies.
The World Health Organization recommends Pfizer's nirmatrelvir/ritonavir for non-severe COVID-19 patients at highest risk of hospitalization, reducing hospital admissions by 84 per 1,000 patients. The guideline also suggests using remdesivir for high-risk patients and acknowledges cost and resource implications.
Recent advances in nanomaterial-based antiviral strategies have generated promising results, including antiviral nanodrugs, drug nanocarriers, and nanovaccines. These nano-sized particles can be useful for targeted delivery of antiviral treatments, leading to improved efficacy and reduced systemic toxicity.
Researchers developed a solid-state photocatalyst using TiO2 and CuO nanoclusters to inactivate various variants of SARS-CoV-2. The material is effective under both darkness and indoor light, making it suitable for reducing COVID-19 infection risk in indoor environments.
Researchers developed a protein-based antiviral nasal spray that thwarts infection by interfering with the virus' ability to enter cells. The treatment neutralizes all tested SARS-CoV-2 variants, including omicron subvariants, and is more cost-effective and self-administerable than current antibody therapies.
Researchers from Trinity College Dublin have discovered how SARS and MERS coronaviruses block the induction of antiviral proteins, preventing a strong immune response. This finding has potential implications for developing new therapeutic options to treat COVID-19 and future deadly coronaviruses.
Scientists are working on understanding the interplay between flaviviruses and mitochondria in hopes of finding new treatment options. By deciphering this process, researchers may be able to find broad-spectrum therapeutic targets for diseases like Zika, dengue, and West Nile.
An analysis of patient-reported data on molnupiravir suggests improved outcomes for most COVID-related symptoms, including loss of smell and fatigue. The drug also showed reduced symptom progression in non-hospitalized patients with high-risk conditions.
New data from the MOVe-OUT trial reveals that molnupiravir significantly reduces SARS-CoV-2 infection within three days of treatment. In contrast, those receiving a placebo took up to five days to clear the virus. The study confirms molnupiravir's effectiveness in accelerating viral RNA decline and eliminating infectious virus.
A new analysis of data on molnupiravir shows the drug effectively clears active SARS-CoV-2 virus in both immunocompromised and non-immunocompromised patients. The study found similar reductions in viral replication and no infectious virus detected after treatment, indicating equal efficacy in both groups.
Researchers at Karolinska Institutet in Sweden have developed a novel strategy to identify potent miniature antibodies, so-called nanobodies, against emerging SARS-CoV-2 variants. The approach led to the discovery of multiple nanobodies that effectively blocked infection with different SARS-CoV-2 variants.
Researchers found that sulforaphane inhibits replication of SARS-CoV-2 and HCoV-OC43 coronaviruses in cells and mice, reducing viral burden by up to 50%. Sulforaphane also helps control immune response and protects against lung injury.
Researchers at Yale have identified a remdesivir-resistant variant of the SARS-CoV-2 virus in an immunocompromised patient. The discovery raises concerns about drug resistance in COVID-19 patients, particularly those with weakened immune systems.
Researchers at the University of North Carolina at Chapel Hill have developed a new oral compound that is as effective as molnupiravir in reducing disease in mice, showing promise for treating COVID-19. The pill form of remdesivir could make it accessible for early treatment and reduce hospitalization rates.
BGE-175 effectively prevents death in a mouse model of COVID-19 by reversing immune aging, suggesting its potential to protect elderly patients hospitalized with COVID-19. The drug restores the immune system to a more youthful state by blocking the PGD2-DP1 pathway.
Researchers have discovered that sea sponges themselves produce biologically active compounds, including terpenes with potential malaria-fighting properties. This finding represents a 'fundamental shift' in the field and opens up new avenues for drug discovery using animals as vessels.
Researchers found that the Pfizer antiviral drug Paxlovid still quashes COVID by targeting a key protein involved in replicating the virus. The study also identified signs of emerging mutations, indicating an urgent need for new drugs to combat potential resistance.
Researchers at La Jolla Institute for Immunology have developed two human antibodies that target Ebola virus and Sudan virus, showing promise for a powerful antiviral therapy. The antibodies, 1C3 and 1C11, can block three glycoprotein sites on the virus at once and target the fusion machinery used by the viruses to infect host cells.
A new study found that making hepatitis C screenings a default order for patients who meet guidelines doubled the rate of screenings among those recommended. The no-click system resulted in an 80% screening rate, compared to 42% under a previous alert system.
Aled Edwards emphasizes the importance of basic and applied research in developing effective COVID-19 vaccines. He also stresses the need for better vaccination implementation, increased global access to vaccines, and a cultural shift towards viewing access to new medicines as a right rather than an asset.
Lab tests show antiviral therapies like remdesivir, molnupiravir, and nirmatrelvir remain effective against the BA.2 variant. Some monoclonal antibodies, such as Evusheld, also appear to be more effective against BA.2 than earlier strains.
Researchers found that tannic acid targets the RBD protein and enzymes involved in viral entry and replication, suggesting its potential as a preventative or therapeutic agent. The polyphenol's low toxicity and anti-inflammatory properties make it an attractive alternative to existing antivirals.
Researchers discovered that combining polymerase and exonuclease inhibitors reduces SARS-CoV-2 replication by 10 times more than single polymerase inhibitors. This combination approach has great potential to stop the spread of COVID-19 and other coronavirus diseases.
Researchers developed a two-step synthesis route for NK0238, an amino acid-derived pesticide, with high atom economy and yield. The compound exhibited broad antiviral activity against multiple plant viruses, outperforming existing agents in terms of efficacy.
The World Health Organization (WHO) has conditionally recommended molnupiravir for patients with non-severe COVID-19 who are at highest risk of hospitalization, including those with weak immune systems or chronic diseases. The drug is expected to reduce the risk of hospital admission and time to symptom resolution.
A modeling study suggests that breast cancer overdiagnosis may occur in about 15% of screen-detected cases, rather than the estimated 30%. This could spare around 25,000 women unnecessary treatment. Researchers used data from the Breast Cancer Surveillance Consortium to estimate the rate of overdiagnosis.
A joint research team from Peking University developed a fine-scale library of pH-sensitive polymeric nanoprobes to accurately measure acidification levels of virus-infected cell membranes or viral envelopes. The polymer, GPS6.8, has broad-spectrum and efficient antiviral effects.
A new study found that bovine lactoferrin, a protein in cow milk, is effective against various SARS-CoV-2 variants, including the WA1, B.1.1.7, and Delta variants. The research suggests that bovine lactoferrin could be used as a preventive or post-exposure treatment for COVID-19.
Researchers found that Neem bark components target a wide range of viral proteins, suggesting its potential as an antiviral agent against emerging coronavirus variants. The study showed the bark extract was effective in reducing virus replication and spread in SARS-CoV-2 human lung cells.
A UC Riverside-led study has identified a potential antiviral therapy for SARS and SARS-like coronaviruses by targeting the papain-like protease enzyme. The research reveals that subgroup 2b PLpros selectively target specific host immune pathways, making them a promising target for future coronavirus therapeutics.
A study by Henry Ford Health System found that hepatitis C patients treated with direct-acting antivirals are less likely to be hospitalized or seek emergency care for related health issues. The study's lead author notes that curing the virus improves overall patient health and reduces the risk of developing other conditions.
A team of scientists has identified specific interferon-alpha subtypes that elicit a strong immune response against Sars-Cov-2. These subtypes were found to be highly effective in suppressing the virus, even when combined with antiviral drugs like remdesivir.
Researchers identified a powerful combination of antivirals that inhibit the growth of SARS-CoV-2 virus in human lung cells and mice. The combination of brequinar with either remdesivir or molnupiravir was found to be more potent than individual drugs, suggesting potential for reducing hospitalizations and deaths.
Researchers at Uppsala University have designed a molecule that inhibits the replication of coronaviruses, including the new variant, with great potential for developing an antiviral drug. The molecule has been shown to be effective against both old and new variants, offering hope for treatment options.
A clinical trial of niclosamide in COVID-19 patients found signals of benefit warranting further study. The medication showed potential in reducing contagiousness and symptoms, particularly in higher-risk populations.
Researchers have discovered a streamlined two-step synthesis strategy to produce neoechinulin B and its derivatives, exhibiting strong anti-HCV and anti-SARS-CoV-2 activities. The novel process utilizes a piperazine-2,5-dione derivative and tetra-n-butylammonium fluoride (TBAF) as key reagents.
Researchers have identified a powerful combination of antivirals to treat COVID-19 by combining brequinar with remdesivir or molnupiravir. The combinations inhibited the SARS-CoV-2 virus in human respiratory cells and mice, suggesting increased potency compared to individual drugs.
A new study reveals that the Omicron variant is sensitive to inhibition by the interferon response, an unspecific immune reaction present in all body cells. This provides the first explanation for why COVID-19 patients infected with Omicron are less likely to experience severe disease.
Researchers at the University of Missouri identified 46 specific mutations in the Omicron variant that enable it to evade pre-existing antibodies. These mutations are particularly prevalent in the region where antibodies bind to the virus, making them a key target for future antiviral treatments.
A randomized controlled trial found that remdesivir reduced the need for mechanical ventilation in hospitalized patients with COVID-19. The study involved 1282 patients and showed that those treated with remdesivir were able to come off oxygen and ventilators sooner than those receiving standard care.
Northwestern University scientists have identified a key mechanism used by the Zika virus to evade the antiviral response of host cells. The study reveals how the virus suppresses interferon signaling to gain access to cells, providing a new target for antiviral therapeutics.
A new study sheds light on the molecular interactions between remdesivir and various viruses, revealing why it works against SARS-CoV-2 but not others like influenza. The findings aim to develop broad-spectrum therapies for future pandemics.
Researchers create plan for proactively developing drug cocktails against virus families, aiming to provide effective treatments in weeks, not months. The approach prioritizes combination therapy to reduce disease spread and limit viral adaptation.
Researchers developed a high-throughput platform to screen for new class of coronavirus antiviral compounds, targeting the macrodomain protein. The platform identified existing drugs that block macrodomain activity, including dasatinib, which shows promise as a potential treatment for COVID-19 and other coronaviruses.
Scientists at Gladstone Institutes developed a new class of antiviral therapy that can track the evolution of SARS-CoV-2, reducing the chance of reduced efficacy against new variants. The single-dose intranasal treatment showed significant reduction in viral load and prevented disease in animals.
The COVID-19 pandemic drove significant advancements in pharmaceutical technology, with mRNA-based vaccines proving highly effective. Oral antiviral pills, such as Merck's molnupiravir and Pfizer's PF-0732133, showed promise in reducing hospitalization and death rates among unvaccinated individuals.
Researchers have successfully determined the structure of the Lassa viral polymerase, a key component in viral replication, using cryo-electron microscopy. This breakthrough provides crucial insights into how to design drugs that can stop the infection, offering hope for developing an effective antiviral.
Researchers at Georgia State University have developed a new candidate antiviral drug, 4’-FlU, which shows potent activity against SARS-CoV-2 and other respiratory RNA viruses. The study demonstrates that 4’-FlU induces termination of the viral polymerase, aborting replication and offering a strong therapeutic asset.
Researchers at Duke University have identified chemical compounds that can latch onto the coronavirus's 3D RNA structures and block replication. The compounds, which target the virus's RNA specifically, offer a new mechanism of action against COVID-19.
Scientists at the University of Nottingham found a plant-based antiviral treatment to be effective in blocking the highly infectious SARS-CoV-2 Delta variant. The novel natural antiviral drug, thapsigargin, was shown to trigger a broad-spectrum host-centred antiviral innate immune response against all variants of the virus.
A gene-silencing therapy harnessing nanoparticles called small extracellular vesicles (sEVs) for drug delivery has protected against Zika virus transmission in pregnant mice to the mouse fetuses. The treatment reduced fetal neurological damage, including virus-induced brain shrinkage.
A Yale team has discovered an RNA molecule, SLR14, that stimulates the body's early antiviral defense system to protect against SARS-CoV-2 variants. This therapy holds promise as a new class of RNA therapeutics for treating COVID-19 in immunocompromised patients.
Paxlovid demonstrates significant efficacy against SARS-CoV-2 virus, reducing hospitalization and death risks in adult patients by up to 89%. The treatment's development involved cutting-edge X-ray technology from the Advanced Photon Source.
A modified version of remdesivir, a COVID-19 treatment, has shown high effectiveness in suppressing SARS-CoV-2 replication and transmission when given orally. The study found that the oral prodrug could be a powerful tool for healthcare workers to combat highly infectious variants.
Scientists have engineered enzymes to manufacture molnupiravir, resulting in a shorter and higher-yielding synthesis. The new method reduces the risk of hospitalization and death from COVID-19 for newly diagnosed patients, showing promise as an antiviral treatment.
Researchers have discovered a potential new treatment for COVID-19 by targeting the pentose phosphate pathway, which is necessary for SARS-CoV-2 replication. The study found that inhibiting this pathway with benfooxythiamine suppresses viral replication and reduces virus production.
Researchers identified two nanobodies that specifically target and stabilize the tetrameric form of SARS-CoV-2 non-structural protein Nsp9, potentially repressing viral replication. These findings suggest a new antiviral strategy for diagnosis and treatment against COVID-19.
Scientists have identified the molecular origins of recombination in RNA viruses, a process that can lead to the emergence of new variants. The study reveals a new class of antiviral drugs that target this mechanism, but warns of potential risks when used in large quantities.
A meta-analysis of randomized controlled trials found lactoferrin to have promising efficacy in reducing the risk of respiratory tract infections, including COVID-19. Lactoferrin may also play a beneficial role in managing symptoms and recovery for patients suffering from RTIs.
University of Illinois Chicago researchers discovered a function of mammalian target of rapamycin complex 2 in an antiviral defense mechanism, limiting HSV-1 virus infection through rapid activation of antiviral immunity. The protein complex protects the host by preventing encephalitis and possible death due to HSV-1 infection.